Angiosarcoma of the scalp

Summary

Angiosarcoma of the scalp (MONDO:0022454) is a disease. A subtype of head and neck cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	angiosarcoma of the scalp
Mondo ID	MONDO:0022454
Anatomy (UBERON)	UBERON:0000403
Is cancer (heuristic)	no

Also known as: angiosarcoma (disease) of scalp · scalp angiosarcoma (disease)

Disease family

This is a subtype of head and neck cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › head and neck cancer › angiosarcoma of the scalp

Related subtypes (15): nasal cavity cancer, head and neck carcinoma, skull cancer, ocular cancer, malignant cranial nerve neoplasm, malignant ear neoplasm, tongue cancer, cheek mucosa cancer, malignant carotid body paraganglioma, salivary gland cancer, hard palate cancer, gingival cancer, lip cancer, malignant tumor of neck, malignant tumor of floor of mouth

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.